NCT02812524 - Ipilimumab for Head and Neck Cancer Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 18, 2016

Primary Completion Date

September 21, 2019

Study Completion Date

December 31, 2025

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG

Intratumoral Ipilimumab

Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.

Trial Locations (1)

97213

Portland Providence Medical Center, Portland